Skip to content
User

Chuck Akre

Akre Capital Management

Chuck Akre SOPHIA GENETICS SA stake

total: 85

Akre Capital Management SOPH trades

Total transactions:
4
New positions:
1
Added:
3
Held since:
2024 Q1
Held for:
10 quarters
Latest activity:
2025 Q2
According to 2026 Q2 report, Chuck Akre holds 3,719,140 SOPHIA GENETICS SA (SOPH) shares with a market value of roughly $21.46M accounting for 0.42% of the overall portfolio. To date, the estimated cost basis is nearly $3.94 for "buy" trades. Akre Capital Management first purchased SOPH in 2024 Q1, initially acquiring 287,699 shares. Since the initial investment in SOPHIA GENETICS SA (SOPH), Akre Capital Management has made 3 more transactions.

How many SOPH shares does Chuck Akre currently hold?

According to 2026 Q2 report, Chuck Akre holds 3,719,140 shares of SOPHIA GENETICS SA (SOPH), valued at around $21.46M.

When did Chuck Akre buy SOPHIA GENETICS SA (SOPH)?

Chuck Akre first invested in SOPHIA GENETICS SA (SOPH) in 2024 Q1 at the reported quarter-end price of $4.93 per share.

What's the cost basis of Akre Capital Management's SOPH stake?

The estimated cost basis for SOPHIA GENETICS SA (SOPH) stake is around $3.94 per share. This represents their average reported price* across all buy transactions

Estimated cost basis*

Weighted AVG buy price:
$3.94

Chuck Akre's historical trades in SOPHIA GENETICS SA

4 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2025 Q2
0.11%
3,719,140
$3.10
$11,529,334
+66.22% (+1,481,636)
+0.04%
2024 Q3
0.07%
2,237,504
$3.65
$8,166,890
+16.51% (+317,072)
+0.01%
2024 Q2
0.08%
1,920,432
$4.58
$8,795,579
+567.51% (+1,632,733)
+0.07%
2024 Q1
0.01%
287,699
$4.93
$1,418,356
new
+0.01%
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.